Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | STAT6 | P42226 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30546542 | 0.88 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL28472473 | 0.85 | CYP2C19 (0.41) | ALDH1A1FFAR3CYP2C19THPOLMNA | |
| SCHEMBL7896231 | 0.82 | CYP1A2 (0.33) | — | |
| SCHEMBL6009787 | 0.78 | ALOX5 (0.40) | ALDH1A1 | |
| SCHEMBL1536298 | 0.76 | GRM2 (0.35) | FFAR3 | |
| SCHEMBL4579579 | 0.76 | ALDH1A1 (0.40) | ALDH1A1FFAR3CYP2C19MAPK1TP53 | |
| SCHEMBL1001103 | 0.74 | ALDH1A1 (0.35) | ALDH1A1FFAR3 | |
| SCHEMBL1515659 | 0.74 | GRM8 (0.44) | — | |
| SCHEMBL12988135 | 0.74 | ALDH1A1 (0.35) | ALDH1A1FFAR3 | |
| SCHEMBL28317712 | 0.72 | ARG1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515943-B | Oxadiazole derivatives | 住友制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| US-20120244122-A1 | Peptides for the Treatment of HCV Infections | CONCERT PHARMACEUTICALS, INC. | 2012-09-27 | — | — | US | disclosed |
| US-20090175824-A1 | Peptides for the treatment of HCV infections | CONCERT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175824-A1 | Peptides for the treatment of HCV infections | DPP4, ZC3HAV1, CTSC | ALDH1A1 4360/4885FFAR3 3174/4885CYP2C19 2264/4885 |
| US-20120244122-A1 | Peptides for the Treatment of HCV Infections | HAVCR2, VIP, PEPD | ALDH1A1 4573/4885FFAR3 1237/4885CYP2C19 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.